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Wereported previously that anti-CD3mAb treatment before hematopoietic cell transplantation (HCT) prevented
graft-versus-host disease (GVHD) and preserved graft-versus-leukemia (GVL) effects inmice. These effects were
associated with downregulated donor T cell expression of tissue-speciﬁc homing and chemokine receptors,
marked reduction of donor Tcellmigration intoGVHD target tissues, anddeletion of CD103þ dendritic cells (DCs)
in mesenteric lymph nodes (MLN). MLN CD103þ DCs and peripheral lymph node (PLN) DCs include CCR7þ and
CCR7 subsets, but the role of these DC subsets in regulating donor T cell expression of homing and chemokine
receptors remain unclear. Here, we show that recipient CCR7þ, but not CCR7, DCs in MLN induced donor T cell
expression of gut-speciﬁc homing and chemokine receptors in a retinoid acid-dependent manner. CCR7 regu-
lated activated DCmigration from tissue to draining lymph node, but it was not required for the ability of DCs to
induce donor T cell expression of tissue-speciﬁc homing and chemokine receptors. Finally, anti-CD3 treatment
depleted CCR7þ but not CCR7 DCs by inducing sequential expansion and apoptosis of CCR7þ DCs in MLN and
PLN. Apoptosis of CCR7þDCswas associatedwithDCupregulation of Fas expression andnatural killer cell but not
T, B, or dendritic cell upregulation of FasL expression in the lymph nodes. These results suggest that depletion of
CCR7þ host-type DCs, with subsequent inhibition of donor T cell migration into GVHD target tissues, can be an
effective approach in prevention of acute GVHD and preservation of GVL effects.
 2014 American Society for Blood and Marrow Transplantation.INTRODUCTION
Allogeneic hematopoietic stem cell transplantation is a
curative therapy forhematologicalmalignancies (ie, leukemia
and lymphoma), owing to the graft-versus-leukemia/
lymphoma (GVL) effect mediated by alloreactive T cells, but
graft-versus-host disease (GVHD) mediated by the same
alloreactive T cells remains as a major obstacle [1-5]. It has
long been proposed that in the pathogenesis of acute GVHD,
recipient hematopoietic antigen-presenting cells (APCs), such
as dendritic cells (DCs), play a major role in initiating alloge-
neic T cell activation and induction of acute GVHD [5-10].
Critical cellular interactions occur in secondary lymphoid
organs, such asmesenteric lymph nodes (MLN), that function
as the meeting ground between host APCs and donor T cells
[11,12]. After being activated by total body irradiation or
chemotherapy, recipient DCsmigrate from tissues to draining
lymph nodes (LN), where they induce donor T cell expressionedgments on page 927.
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Activated T cells subsequently migrate to epithelial tissues,
such as the gut and skin, to cause GVHD [15,16].
CCR7 expressed by DCs and the CCR7 ligands, CCL19 and
CCL21, expressed in LNs, mediate the migration of activated
DCs from tissues into LNs [17], and proinﬂammatory cyto-
kines such as IFN-g augment expression of CCR7 by DCs and
increase release of the CCR7 ligands in LNs to enhance this
migration [18,19]. Donor Tcells are induced to express tissue-
speciﬁc homing and chemokine receptors in draining LNs
[13,20], although lymphotoxin-aedeﬁcient mice lacking
Peyer’s patches and lymph nodes still developed acute GVHD
[21,22]. In the MLN, T cells interact with CD103þ DCs and
upregulate expression of gut-homing receptors, including
a4b7 and CCR9 [14,23], and donor T cell expression of a4b7
has been shown to be important for development of gut
GVHD [24]. In peripheral lymph nodes (PLN), T cells interact
with DCs to upregulate expression of skin-homing receptors,
including E-ligand, P-ligand, CCR4, and CCR10 [23,25,26].
These tissue-speciﬁc homing and chemokine receptors and
chemokine gradients guide T cell inﬁltration of GVHD target
tissues [13,27-29], and nonhematopoietic APCs in the GVHD
target tissue may upregulate MHC and mediate alloreactive
T cell expansion in the tissue [30,31].Transplantation.
Figure 1. CCR7þ DC subset in MLN was necessary for induction of gut-homing receptor expression by donor T cells. (A) Mononuclear cells of MLN and PLN from BALB/
c mice 7 days after treatment with PBS or anti-CD3 (5 mg/kg) were stained for CD11c, CCR7, and CD103. Gated CD11cþ cells are shown as CCR7 versus CD103 staining.
A representative ﬂow cytometry pattern and the percentage and yield (mean  SE, n ¼ 4) of CCR7þ DC subsets and total CD11cþ cell yield from 1 of 4 replicate
experiments are shown. (B) CD11cþCD103þ DCs from MLN of untreated BALB/c mice were sorted into CCR7þ and CCR7 subsets. Each subset (.05  106) was
cocultured with C57BL/6 T cells (.1 106) for 4 days. Thereafter, cultured cells were stained with CD4, CD8, a4b7, and CCR9. Gated CD4þ or CD8þ T cells are shown as
CD4 or CD8 versus a4b7 or CCR9 staining. A representative ﬂow cytometry pattern and the percentages (mean  SE) of a4b7þ or CCR9þ cells among CD4þ or CD8þ
T cells from 1 of 3 replicate experiments are shown. (C) Total RNA was isolated from sorted CCR7þ and CCR7 DCs from MLN and PLN of untreated BALB/c mice, and
RALDH expression was analyzed by real-time PCR. Relative expression levels (mean  SE) from 3 replicate experiments are shown. (D-F) Seven days after treatment
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hematopoietic APCs did not prevent induction of acute GVHD
[32], and recipient nonhematopoietic APCs were sufﬁcient to
induce donor T cell activation/expansion in GVHD target
tissues, especially in gut tissue, and induce lethal GVHD [33].
On the other hand, a previous report indicates that retinoic
acid (RA)-producing CD103þ DCs in MLN play an important
role in imprinting T cell expression of a4b7 and CCR9 [14].
RA-induced donor T cell expression of gut-speciﬁc homing
and chemokine receptors a4b7 and CCR9 in MLN, and
blockade of RA signaling, prevented donor T cell upregula-
tion of a4b7 and CCR9 expression and markedly reduced the
severity of gut GVHD [34,35]. The important role of a4b7 in
mediating alloreactive T cell migration into gut tissues has
also been demonstrated by others, in both animal models
and patients [24,36,37].
Consistently, we observed that depletion of CD103þDCs by
anti-CD3preconditioningpreventeddonor Tcell expression of
a4b7 and CCR9 and prevented GVHD in the gastrointestinal
tract and elsewhere [38]. We have recently observed that
CD103þ DCs in MLNs include both CCR7þ and CCR7 subsets.
DCs in PLNs are CD103 but also include CCR7þ and CCR7
subsets. In the current study, we attempted to determine
whether these2DCsubsets differ in their ability to produceRA
and induce tissue-speciﬁc homing and chemokine receptors
by donor T cells. We also evaluated the effects of anti-CD3
preconditioning on CCR7þ and CCR7 DC subsets, as it has
beenproposed that the CCR7þ subset comprises activated DCs
that migrate from inﬂamed tissues into draining LNs [17].
MATERIALS AND METHODS
Mice
C57BL/6 (CD45.2), congenic C57BL/6 (CD45.1) and BALB/c mice were
purchased from NCI Laboratories (Frederick, MD). CCR7/ C57BL/6
(CD45.2) mice were purchased from the Jackson Laboratory. OT-I C57BL/6
(CD45.2) mice were a gift from Dr. Hua Yu (City of Hope National Medical
Center, CA). All animals weremaintained in a pathogen-free room at the City
of Hope Research Animal Facility. Male mice 8 to 10 weeks of age were used
in the current studies. Animal use protocols were approved by the institu-
tional review committee.
Chemicals
RA and its receptor antagonist, LE135, were respectively purchased from
Sigma (St. Louis, MO) and Tocris Bioscience (Bristol, United Kingdom), dis-
solved in DMSO (100 mM), stored at 20C, and protected from light.
Ovabumin (OVA) was purchased from Sigma (USA). Collagenase D (11 088
858 001) and DNasel recombinant (04 536 282 001) were purchased from
Roche Laboratories (Nutley, NJ).
Cell Puriﬁcation
Production of anti-CD3 mAb 145-2C11 has been described in our pre-
vious publication [39]. To enrich dendritic cells, the MLNs and/or PLNs were
harvested and digested at 37C in RPMI 1640medium containing 0.5 mg/mL
collagenase D and 50 U/mL recombinant DNasel for 10 to 20 minutes. Tis-
sues were disaggregated, mononuclear cells were collected, and CD11cþ
cells were enriched by magnetic antibody cell separation. Enriched CD11cþ
cells were used for further separation of CCR7þ and/or CD103þ cells by FACS.
CD4þ and CD8þ T cells were obtained from mouse spleens by magnetic
antibody cell separation (purity > 95%).
Flow Cytometric Analysis
The following anti-mouse mAbs were purchased from BD Biosciences
Pharmingen (San Jose, CA), eBioscience (San Diego, CA), BioLegend
(San Diego, CA), or R&D Systems (Minneapolis, MN): TCRb (H57-597), CD4with PBS or anti-CD3, CD11cþ DCs from host-type BALB/c MLN were sorted. The s
cocultured with splenic CD4þ and CD8þ T cells (.2  106) from donor-type C57BL/6 (
with the donor T cells in the presence or absence of RA (E); ﬁnally, the sorted CD11cþ
presence or absence of RA antagonist LE135 (1 mM) (F). After culture for 4 days, expres
Percentages (mean  SE, n ¼ 4) of a4b7þ or CCR9þ cells among CD4þ or CD8þ T cell(RM4-5), CD8a (53-6.7), CD11c (HL3), CD103 (M290), a4b7 (DATK32), CCR9
(CW-1.2), CD45.2 (104), CCR7 (4B12), Fas/CD95 (554258), FasL/CD178
(MFL3), CD49b (DX5), CD90.2/Thy1.2 (30-H12), CD19 (eBio1D3), Annexin V
(17-8007-72). Fluorescence-activated cell sorting (FACS) was performed
with a 4-laser MoFlo Immunocytometry System (Dako, Glostrup, Denmark)
or CyAn immunocytometry system (Dako Cytomation, Fort Collins, CO), and
data were analyzed with FlowJo software (TreeStar, Ashland, OR), as
described previously [40].
Quantitation of Gene Expression by Real-Time RT-PCR
Isolation of total tissue RNA and synthesis of ﬁrst strand cDNA have been
described previously [38]. mRNA was quantiﬁed by real-time quantitative
PCR using Applied Biosystems 7300 Fast Real-Time PCR System (Applied
Biosystems, Forest City, CA). The following primer sequences were obtained
from previous reports: RALDH2 [41]: Forward: 50-TGCATTCA-
CAGGGTCTACCGA-30 and Reverse: 50-TGCCTCCAAGTTCCAGAGTT-30 .
TUNEL Assay of DC Apoptosis
Eight hours after treatment of BALB/c mice with anti-CD3 mAb (5 mg/kg
i.v.), MLNs were harvested, ﬂash frozen, and cut into 10-mm sections. Slides
were then stainedwith TUNEL (Roche), DAPI, goat anti-mouse CCR7 (Abcam,
Cambridge, MA), and biotin-CD11c (Ebioscience) and then imaged with the
use of an LSM 510 Meta Inverted 2 Photon Confocal Microscope (Zeiss,
Oberkochen, Germany). Images were taken with a 40 water objective
(Leica, Buffalo Grove, IL) and analyzed for expression of CCR7 and apoptosis
using an LSM Image Browser.
Statistical Analysis
Differences betweenmeans were evaluated according to the unpaired 2-
tailed Student t-test.
RESULTS
Host CCR7þ DCs in MLNs Induced Alloreactive Donor
T Cell Expression of Gut Homing and Chemokine
Receptors in a RA-dependent Manner
Our previous report showed that preconditioning with
anti-CD3 mAb 7 days before hematopoietic cell trans-
plantation (HCT) prevented acute GVHD and preserved the
GVL effect in recipients conditioned with myeloablative total
body irradiation. Prevention of acute GVHD was associated
with depletion of CD103þ DCs, reduced expression of tissue
homing and chemokine receptors by donor T cells, and
reduced donor T cell migration into GVHD target tissues,
such as gut and skin [24]. Expression of CCR7 on DCs was
proposed to mediate DC migration from tissue to draining
LNs [17], but the role of CCR7þ DC in inducing donor T cell
expression of tissue homing and chemokine receptors re-
mains unclear. We evaluated the role of host-type CCR7þ and
CCR7 DCs in inducing donor T cell expression of tissue
homing and chemokine receptors. We also evaluated the
impact of anti-CD3 treatment on depletion of host-type
CCR7þ and CCR7 DC subsets.
We found that host-type CD103þ DCs in MLN included
CCR7þ (w30%) and CCR7 subsets (Figure 1A). The CD103
DCs that predominate in PLN also included CCR7þ (w30%)
and CCR7 subsets. Although anti-CD3 treatment did not
signiﬁcantly reduce the total numbers of CD11cþ DCs in MLN
and PLN by 7 days after treatment, anti-CD3 treatment
markedly reduced the percentage and yield of CCR7þ DCs in
both MLN and PLN (P < .01) (Figure 1A, right panels). These
results indicate that anti-CD3 treatment depletes CCR7þ but
not CCR7DCs, and that CCR7þDCs in the draining LNmay be
responsible for imprinting T cell expression of tissue-speciﬁc
homing and chemokine receptors.orted CD11cþ cells (.1  106) from PBS- or anti-CD3etreated mice were ﬁrst
D); then, the sorted CD11cþ DCs from anti-CD3etreated mice were cocultured
DCs from PBS-treated control mice were cultured with the donor T cells in the
sion of a4b7 and CCR9 by the cultured T cells was analyzed by ﬂow cytometry.
s are shown.
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inducing donor T cell expression of tissue-homing receptors,
we decided to mechanistically focus on MLN CCR7þ DC and
their capacity to imprint gut-homing receptors a4b7 and
CCR9. Accordingly, recipient-type BALB/c MLN CD11cþ DCs
were sorted into CD103þCCR7þ and CD103þCCR7 subsets
and cultured with sorted donor-type C57BL/6 splenic CD4þ
and CD8þ T cells for 4 days. The percentage of a4b7þ and
CCR9þ CD4þ and CD8þ T cells was approximately 5- to 15-
fold higher in cultures with CCR7þ DCs, compared with
cultures with CCR7 DCs (P < .001) (Figure 1B). This resultFigure 2. Preconditioning with anti-CD3 mAb inhibited CCR7þ DC migration from gut
CD3 (5 mg/kg) or PBS. Seven days after treatment, mice were given 50 mg OVA orally.
with sorted CD8þ T cells (.2  106) from OT-I TCR transgenic C57BL/6 mice, and expre
FACS pattern of a4b7þ and CCR9þ cells among OT-I CD8þ T cells (left) and the perce
representative results from 1 of 3 replicate experiments. (C) CD45.1þ congenic C57BL/6
OT-I CD8þ T cells from CD45.2þ OT-I transgenic C57BL/6 mice were injected into the t
OVA orally or 5 mg OVA i.p. Three days later, expression of a4b7 and CCR9 by CD45.2þ
and the percentages (mean  SE) of a4b7þ or CCR9þ cells among OT-I CD8þ T cells (indicates that CD103þCCR7þ but not CD103þCCR7 DCs in
MLNs induce expression of gut-homing a4b7 and CCR9 re-
ceptors by allogeneic T cells.
Production of RA by DCs in MLNs is required for induction
of T cell expression of a4b7 and CCR9 [42], and the enzyme
RALDH2 is needed to metabolize vitamin A into RA [43]. We
found that expression levels of RALDH mRNA were 5-fold
higher in CD103þCCR7þ DCs than in CD103þCCR7 DCs
fromMLNs (P< .01), but expression of RALDHmRNAwas not
detected in either CCR7þ or CCR7 DCs from PLN (Figure 1C).
CD11cþ DCs from MLN of mice treated with anti-CD3 had atissue to MLN. (A) Experimental diagram: C57BL/6 mice were treated with anti-
One day later, CD11cþ DCs (.1 106) sorted from MLN were cultured for 4 days
ssion of a4b7 and CCR9 by OT-I T cells was analyzed by ﬂow cytometry. (B) A
ntages (mean  SE) of a4b7þ and CCR9þ cells among CD8þ T cells (right) are
mice were treated with PBS or anti-CD3 (5 mg/kg). Seven days after treatment,
reated CD45.1þ congenic recipients. One day later, recipients were given 50 mg
OT-I CD8þ T cells in MLN was analyzed by ﬂow cytometry. FACS patterns (left)
right) are representative results from 1 of 3 replicate experiments.
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CCR9 by allogeneic CD4þ and CD8þ T cells in an in vitro
culture assay (P < .01) (Figure 1D). Expression of a4b7 and
CCR9 in this assay was restored and greatly enhanced by
adding RA (10 nM) to the cultures (P < .01) (Figure 1E).
CD11cþ DCs fromMLN of control mice induced expression of
a4b7 and CCR9 by allogeneic CD4þ and CD8þ T cells, and
expression of a4b7 and CCR9 was inhibited by adding the RA
receptor antagonist LE135 (1 mM) to the cultures (P < .01)
(Figure 1F). Taken together, these results demonstrate that
expression of gut-homing a4b7 and CCR9 by donor T cells is
induced by recipient MLN CCR7þ DCs through an RA-
dependent mechanism.
Depletion of CCR7þ DCs by Anti-CD3 Treatment Prevented
Tissue DC Migration from Intestinal Lamina Propria to
MLN Early after HCT
In the pathogenesis of GVHD, tissue damage caused by
the conditioning regimen releases proinﬂammatory cyto-
kines and chemokines that activate tissue DCs and upregu-
late their expression of CCR7 so that they migrate to draining
LNs [44]. Because only CCR7þ DCs migrate from gut or skin
tissues to draining LNs [45,46], and as we observed that
treatment with anti-CD3 resulted in the loss of CCR7þ DCs in
MLN and PLN, we tested whether treatment with anti-CD3
mAb prevented DC migration from intestinal lamina prop-
ria to MLN. For this purpose, we used an assay that measures
the ability of DCs to transport orally administered OVA from
the lamina propria to MLN [45].Figure 3. Deﬁciency of CCR7 expression on DCs in MLN of mice did not impair DC’s
receptors. (A) The MLN from wild-typed and CCR7/ C57BL/6 mice were harvested
CD11cþ (left), the percentage (middle), and yield (right) of CD103þ DCs among CD11ch
DCs (.1  106) in MLN from WT and CCR7/ mice were sorted by FACS after magnet
BALB/c mice in U-bottom 96-cell plates for 4 days. Expression of a4b7 and CCR9 by th
replicate experiments.As described in Figure 2A, C57BL/6micewere treatedwith
control PBS or anti-CD3 mAb. The mice were given oral OVA
(50 mg) 7 days after treatment, and on the following day,
CD11cþ DCs were isolated from MLNs and cocultured with
OVA-speciﬁc CD8þ T cells from OT-I TCR-transgenic C57BL/6
mice for 4 days. Induction of a4b7 and CCR9 expression by
OVA-speciﬁc T cells was greatly reduced after stimulation
with DCs from mice treated with anti-CD3 mAb compared
with those from mice treated with PBS (w10% versus 60%,
P< .01) (Figure2B). This result indicates that fewOVA-bearing
DCs migrate from the lamina propria to the MLN after anti-
CD3 preconditioning. These results also indicate that few
CCR7þ DCs remain in the tissues after anti-CD3 treatment.
We evaluated the effect of anti-CD3 treatment on
migration of DC from the lamina propria to the MLN and on
the subsequent interaction of DC with T cells in MLN.
Accordingly, CD45.1þ C57BL/6 mice were treated with either
control PBS or anti-CD3 mAb. Seven days after treatment,
CD8þ T cells (3  106) from CD45.2þ OT-I TCR-transgenic
C57BL/6 donors were injected into the anti-CD3etreated or
control PBSetreatedmice, and on the following day, themice
were given OVA by oral administration (PO) or intra-
peritoneal injection (IP). To stimulate T cells, oral OVA must
be transported from lamina propria to MLN by DCs, but IP-
OVA can directly reach MLN in the absence of DC migration
from lamina propria to MLN.
Three days after IP or PO administration of OVA, more
than 32% of the CD45.2þ OT-I CD8þ T cells from MLNs of
recipients treated with PBS expressed a4b7 and CCR9,ability to induce donor T cell expression of gut-tropic homing and chemokine
and mononuclear cells were stained for CD11c and CD103. The yield of total
igh cells are shown (mean  SE). Each group contains 4 mice. (B) CD11cþCD103þ
ic enrichment of CD11cþ cells and cocultured with CD4þ or CD8þ T cells from
e cultured T cells was analyzed by ﬂow cytometry. Mean  SE is shown from 4
Figure 4. Treatment with anti-CD3 mAb induced sequential expansion and apoptosis of CCR7þ DC in MLN and PLN. (A,B) BALB/c mice were treated with anti-CD3
mAb (5mg/kg). (A-C) At the indicated time points, mononuclear cells from MLN and PLN were analyzed for the percentages and numbers of total CD11cþ DCs and the
CD11cþCCR7þ and CD11cþCCR7 subsets by ﬂow cytometry. Results are shown as the kinetic curve of the mean  SE of 5 replicate experiments. (D) Eight hours after
antibody injection, MLNs were harvested (n ¼ 4 mice) and tissue sections were stained as follows: TUNEL indicating apoptosis (green), CD11c (red), CCR7 (blue), and
DAPI (light blue). Slides were imaged at 40 magniﬁcation. Insets show 8 magniﬁed view of image. Arrows indicate apoptotic CCR7þ DCs (lower panel) and
nonapoptotic CCR7 DCs (upper panel). Apoptotic CCR7þ or CCR7 DCs were counted and shown as a percentage of CCR7þ or CCR7 DCs, respectively (n ¼ 4 mice,
mean  SE). (E,F) Eight hours after antibody injection, mononuclear cells fromMLN or PLN were stained for CD11c, CCR7, and Annexin V or Fas. Histograms of Annexin
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MLNs of recipients treated with anti-CD3 mAb expressed
a4b7 or CCR9 (P < .01) (Figure 2C). IP and PO administration
of OVA both induced OVA-speciﬁc T cells to express a4b7 and
CCR9 in PBS-treated mice but not in anti-CD3etreated mice
(Figure 2C). These results suggest that 7 days after treatment
with anti-CD3 mAb, DCs could not migrate from tissue to
MLN (most likely due to the lack of the CCR7þ subset), as
indicated by the absence of a4b7 and CCR9 expression by OT-
I T cells in MLN after oral administration of OVA. Likewise,
pre-existing CCR7þ DCs in the MLN had been eliminated, as
indicated by the absence of a4b7 and CCR9 expression by OT-
I T cells in MLN after IP injection of OVA. Taken together,
these results indicate that conditioning with anti-CD3 mAb
not only depletes the pre-existing CCR7þ DCs in the draining
LNs, but also depletes CCR7þ DCs in the tissues and prevents
DC migration from tissues into LNs.
MLN DCs Deﬁcient in CCR7 Expression Were Still Able to
Induce Donor T Cell Expression of Gut-tropic Homing and
Chemokine Receptors
Although we observed that CCR7þ DC were capable of
imprinting donor T cells in an RA-dependent mechanism
(Figure 1C-F), we wondered whether CCR7 itself was
required for the DC function. Therefore, we tested whether
DC expression of CCR7 was required for their imprinting
donor T cell tissue tropism by comparing DCs fromwild type
(WT) and CCR7/ C57BL/6 mice. We observed that,
compared with WT mice, the yield of total CD11cþ DCs in
MLN of CCR7/mice was reduced more than 2-fold (P< .01)
(Figure 3A, left panel). The percentage and yield of CD103þ
DCs of CCR7/ mice was also markedly reduced (P < .05)
(Figure 3A, middle and right panels). Sorted CD103þ DCs
from MLN of both strains, however, induced donor CD4þ or
CD8þ Tcell expression of a4b7 and CCR9 in an in vitro culture
assay, and no signiﬁcant difference was observed (P > .05)
(Figure 3B). The result is consistent with a previous report
that CCR7 plays important roles in mediating activated DC
migration from tissue to draining LN; this result also in-
dicates that CCR7 itself is not required for DC’s function in
imprinting T cell tissue tropism.
Anti-CD3 mAb Treatment Induced Sequential Expansion
and Apoptosis of CCR7þ DCs in MLN and PLN
Because we observed that treatment with anti-CD3 mAb
depleted CCR7þ DCs in MLN and PLN and prevented DC
migration from gut tissue to MLN (Figure 1,2), we tested
whether this treatment induced apoptosis of CCR7þ DCs. The
percentage and yield of the total CD11cþ DCs and the CCR7þ
andCCR7 subsets inMLNandPLNwerekineticallymeasured
before and after injection of anti-CD3mAb. The total numbers
of CD11cþ DCs in MLN increased 10-fold at w8 hours after
antibody injection, then rapidly decreased by 12 hours, and
reached a nadir at 24 to 48 hours (Figure 4A, left panel). Be-
tween 8 to 12 hours after antibody injection,w90% of CD11cþ
DCs became CCR7þ (Figure 4C, upper row). By 96 hours, the
total numberof CD11þDCs recovered to levels similar to those
observed before the antibody injection (Figure 4A, left panel).
The initial rapid increase and the subsequent decrease of totalV or Fas staining on gated CD11chi CCR7þ cells (blue line) and CD11chi CCR7 cells (bla
Eight hours after anti-CD3 injection (5 mg/kg), mononuclear cells from the MLN and
(H) Thy1.2þ, (I) CD19þ, or (J) CD11cþ cells were shown in histogram of FasL. (G-I) His
control. Negative control is ﬁlled in grey, nonconditioned BALB/c is red, and anti-C
CD11cþ, and negative control. Negative control is ﬁlled in grey, CCR7CD11cþ is red,CD11cþ DCs resulted predominantly from changes in the
CCR7þDC subset, and the recovery at 96 hours came from the
CCR7 (likely de novo developed) subset (Figure 4A, right
panel; Figure 4C). Fluctuations in the numbers of total CD11cþ
DCs, as well as CCR7þ and CCR7 DC subsets in PLNs after
treatmentwith anti-CD3mAb,were similar to those observed
in MLNs, although the onset was delayed by 12 to 24 hours
(Figure 4B,C).
The rapid decrease in the number of CCR7þ DCs 8 to
12 hours after injection of anti-CD3 mAb in MLNs resulted
from apoptosis, as the percentage of TUNELþ DCs was 5-fold
higher in the CCR7þ subset than in the CCR7 subset (P< .01)
(Figure 4D). CCR7þ DCs in MLNs and PLNs had much higher
levels of Annexin V staining compared with CCR7 DCs
(Figure 4E,F). Compared with CCR7 DCs, the increased
apoptosis of CCR7þ DCs was associated with higher expres-
sion of Fas (Figure 4E,F). Additionally, we found that in the
MLN and PLN DX5þ natural killer (NK) cells, but not Thy1.2þ
T, B220þ B, or CD11cþ subsets (CCR7þ or CCR7) dendritic
cells upregulated expression of FasL (Figure 4G-J).
DISCUSSION
We previously showed that treatment with anti-CD3
before HCT prevented GVHD while preserving strong GVL
effects [38]. Prevention of GVHD was associated with
downregulated expression of tissue-speciﬁc homing and
chemokine receptor by donor T cells and depletion of
CD103þ DCs in MLN [38]. In this report, we expand upon
previous results and have shown the following: (1) CD103þ
DCs in MLN included CCR7þ and CCR7 subsets, and CCR7þ
DCs that produced RA were required to induce expression of
gut-homing a4b7 and CCR9 by donor T cells; (2) anti-CD3
treatment before HCT upregulated DC expression of CCR7
and Fas and induced DC apoptosis, likely through Fas/FasL
signaling pathway; and (3) depletion of CCR7þ DCs pre-
vented DC migration from tissue to draining LN and reduced
donor T cell expression of tissue-speciﬁc homing and che-
mokine receptors.
We observed that CCR7þ but not CCR7 DCs in MLNs
expressed high-levels of RALDH, an enzyme needed to
convert vitamin A to RA. CCR7þ but not CCR7 DCs in MLNs
were able to induce expression of gut-homing a4b7 and
CCR9 by alloreactive Tcells in vitro through an RA-dependent
mechanism. In addition, CCR7þ DCs from MLN, but not from
PLN, showed expression of RALDH, the enzyme that catalyzes
conversion of vitamin A to RA. These results indicate that
only activated DCs can induce donor Tcell tissue tropism, and
activated DCs from different tissues have different enzyme
activity that can mediate T cell tissue tropism. This result is
consistent with a previous report that DCs from LN draining
different GVHD target tissues induced donor T cell expres-
sion of tissue-speciﬁc homing and chemokine receptors [20].
We observed that depletion of CCR7þ DCs by anti-CD3
preconditioning resulted from sequential events of DC acti-
vation, DC upregulation of CCR7 and Fas expression, CCR7þ
DC inﬂux into draining LNs, and, ﬁnally, DC apoptosis. In-
jection of anti-CD3 markedly increased serum levels of IL-2,
IFN-g, and IL-6, which peaked w8 hours after injection of
anti-CD3 [47]. These cytokines were reported to activate DC,ck line) are shown. Results are representative of 3 replicate experiments. (G-I)
PLN were stained for DX5, Thy1.2, CD19, or CD11c versus FasL. Gated (G) DX5þ,
tograms are overlaid: with or without anti-CD3-preconditioning and negative
D3-preconditoned is blue. (J) Histograms are overlaid: CCR7þ CD11cþ, CCR7
and CCR7þCD11cþ is blue. Results are representative of n ¼ 4 mice per group.
W. He et al. / Biol Blood Marrow Transplant 20 (2014) 920e928 927upregulate DC expression of CCR7 and Fas, and augment LN
release of CCR7 ligands CCL19 and CCL21 in LN [18,19].
Consistently, we observed that administration of anti-CD3
markedly augmented MLN and PLN release of CCL19 and
CCL21 (He and Zeng: unpublished data). As early as 8 hours
after anti-CD3 treatment, most DCs in MLN and PLN became
CCR7þ, and total numbers of DC and CCR7þ DC increased by
10-fold. At 12 and 48 hours after treatment, total DC and
CCR7þ DC numbers reached a nadir, most likely due to the
apoptosis of CCR7þ DCs, because CCR7þ DCs express high
levels of Fas. At this same time after anti-CD3 injection, DX5þ
NK cells, but not Thy1.2þ T, CD19þ B, or CD11cþ dendritic cells
in MLN and PLN, upregulated FasL. The IL-2-activated FasL-
expressing NK cells may mediate the apoptosis of the
CCR7þ DCs with high-level expression of Fas. Although NK
cells traditionally kill through use of perforin, NK cells acti-
vated in the presence of IL-2 kill via FasL/Fas pathway [48].
Although the speciﬁc mechanisms by which these NK cells
contribute to the apoptosis of CCR7þ cells are still under
investigation, we have observed that IL-2Rg/mice that are
deﬁcient in NK cells fail to deplete CCR7þ DC after anti-CD3
injection, and injection of a FCR-nonbinding anti-CD3 that
stimulates lower levels of IL-2 than FCR-binding anti-CD3
([39,49] and data not shown) only partially depletes CCR7þ
DC (data not shown). Interestingly, despite upregulation of
CCR7þ expression by DCs after anti-CD3 preconditioning,
signiﬁcant expression changes were not seen in other acti-
vation markers, such as CD40, CD80, CD86, and MHCII (data
not shown), although we cannot fully rule out functional
differences in antigen processing/presentation after anti-CD3
conditioning. By 96 hours after anti-CD3 treatment, total DC
numbers recovered to the level before treatment, but they
were all CCR7, which are most likely de novoedeveloped
DCs. Thus, anti-CD3-conditioning induces DC activation,
upregulated expression of CCR7 and Fas, and apoptosis, all in
CCR7þ DCs.
Anti-CD3 preconditioning and depletion of CCR7þ DCs
does not interfere with activation of donor T cells in LN. First,
donor T cells are infused 7 days after anti-CD3 precondition-
ing when serum anti-CD3 is not detectable as previously
described [50]. Second, although anti-CD3 preconditioning
depletes CCR7þ DCs, it does not reduce the total number of
CD11cþ DCs in the MLN and PLN when donor T cells are
infused. The CCR7 DCs are fully capable of stimulating allo-
geneic T cells in vitro and in vivo, comparable to the ability of
DCs from untreated control mice [38]. Five days after HCT,
donor T cell expansion in the host lympho-hematopoietic
tissues is stronger in anti-CD3epreconditioned recipients
compared with the recipients without preconditioning,
although the donor T cells do not migrate to GVHD target
tissues, such as gut and skin, to cause GVHD [38]. Thus, the
injected anti-CD3 had little or no direct effect on alloreactive
donor T cell activation. This regimen differs from previously
reported use of anti-CD3mAb for treatment after HCT, where
the main effect of the antibody is to block activation of allor-
eactive donor T cells in the recipient [51-53].
Depletion of CCR7þDC subset via anti-CD3preconditioning
differs from depletion of DCs by establishing chimeras using
MHC II-deﬁcient bone marrow or depletion of DCs by expres-
sion of diphtheria toxin (DT) receptor and injection of DT or
other antibodies as described in recent publications [32,33].
Anti-CD3 preconditioning and depletion of CCR7þ DCs
(including RA-producing CCR7þ DCs in MLN) prevents GVHD
by impairing donor T cell migration into GVHD target tissues.
The resultswith anti-CD3-preconditioning are consistentwithobservations that blockade of RA signaling downregulated
donor T cell expression of gut-speciﬁc homing and chemokine
receptors and ameliorated gut GVHD [34,35]. The results are
alsoconsistentwithobservations that conﬁningdonorTcells in
host lymphoid tissues by administration of FY720 prevented
GVHD [54].However, depletionofhosthematopoieticAPCsdid
not prevent donor T cell migration into GVHD target tissues
[33], and nonhematopoietic APCs in the target tissues upre-
gulate MHC II and expanded donor T cells that caused GVHD.
In summary, our studies identify CCR7þ DCs in MLNs as a
critical cell population required for induction of gut-homing
and chemokine receptors, a4b7 and CCR9, by donor T cells.
Anti-CD3 preconditioning depletes this DC subset ﬁrst by
CCR7 upregulation followed by induction of apoptosis.
Depletion of CCR7þ DCs may explain how anti-CD3 pre-
conditioning prevents GVHD while preserving GVL effects, as
demonstrated previously [38]. Regimens targeting DC subsets
that imprint donor T cell tissue tropism could be an effective
approach towards controllingGVHDwhile sparingGVLeffects.ACKNOWLEDGMENTS
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